A composition having molecular iodine in combination with a polyol can be used for control and treatment of microbes and infections on biological and non-biological surfaces. Compositions have a combination of molecular iodine (I2) and an acceptable source of iodate (IO3), and a buffering acid (inorganic or organic), in combination with a polyol in an amount of 3-50% by weight. The present compositions can also have prebiotic and probiotic properties on biological surfaces and membranes for the control and treatment of infection as well as the support of growth of commensal microbes and the control of pathogenic microbes.

A method for intranasal delivery of a formulation comprising Botulinum toxin for the treatment of allergic rhinitis involved impregnating an absorbent tip of an applicator with the formulation, the applicator having a rigid rod having the absorbent tip at a distal end thereof, and inserting the applicator straight into a nasal cavity of a patient beneath the lower turbinates to target the nasal- or nasopharynx-associated lymphoid tissue (NALT) and the eustachian tube opening zone of the nasopharynx within the nasal cavity with the absorbent tip.

A sanitizing composition for restoring skin's natural balance of bacteria and/or increasing the production and/or activity of antimicrobial peptides is provided. The sanitizing composition includes about 0.005 wt. % to 15.0 wt. % of an active ingredient that is one or more of a probiotic, probiotic derivative, prebiotic, and a prebiotic derivative and at least one compound that delivers a sanitizing effect.

The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent;
wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T.sub.max value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.

The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a T.sub.max substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

The present invention relates to a composition comprising, preferably consisting of, (i) a single empty liposome, wherein said single empty liposome is selected from (a) an empty liposome consisting of sphingomyelin and cholesterol, wherein the amount of cholesterol is at least 20% (weight per weight); or (b) an empty liposome consisting of sphingomyelin; or (ii) a mixture of empty liposomes; wherein said mixture of empty liposomes comprises (a) a first empty liposome consisting of sphingomyelin and cholesterol, wherein the amount of cholesterol is at least 20% (weight per weight); and (b) a second empty liposome consisting of sphingomyelin; for use in a method of treating or preventing a viral infection in a mammal, preferably in a human.

The present disclosure provides a nasal delivery device with a device body that includes a trigger end and an outlet end. The nasal delivery device also includes a trigger assembly coupled to the trigger end of the device body, a drug container supported by the device body, and a spring-loaded activator assembly supported by the device body and disposed between the trigger assembly and the drug container.

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

A method to prevent, inhibit or treat one or more symptoms associated with disease of the central nervous system by intranasally, intrathecally, intracerebrovascularly or intravenously administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease, in an amount effective, e.g., to provide for cross-correction.

The invention relates to a composition comprising apolactoferrin, optionally in admixture with lactoferrin, carried via liposomes, as well as to products comprising such a composition, and to their use for the prevention and/or treatment of the conditions affecting the respiratory system, in particular the viral infections.